Piper Sandler Maintains Overweight on Tyra Biosciences, Raises Price Target to $56

Piper Sandler analyst Allison Bratzel has maintained an Overweight rating on Tyra Biosciences (NASDAQ: TYRA) and increased the price target from $42 to $56. This adjustment reflects a positive outlook on the company's performance.